PubMed Health⌕ Search

Biomedical subjects

S I Moiseev

Publications and source records attributed to S I Moiseev.

At least 19 recordsLinked to original sources
PubMed2002

[Cytomegalovirus infection in bone marrow transplantation].

AIM: To evaluate frequency and clinical features of CMV infection in patients with hematological malignancies (HM) after autologous and allogeneic stem cell transplantation, protective and therapeutic methods, efficiency of CMV hyperimmune immunoglobulin cytotest (Biotest Pharma). MATERIAL AND METHODS: The trial enrolled 22 patients (group 1) with HM and severe aplastic anemia after allogeneic bone marrow transplantation, 58 patients (group 2) with HM after autologous stem cell transplantation. The patients were examined for CMV infection by serologic methods and PCR. RESULTS: The probabilities of CMV infection were greater in group 1 than group 2--10/22(45%) versus 12/58 (21%), p < 0.05. Clinical signs of CMV disease were pneumonitis (27%), hepatitis (32%), gastroenteritis (9%), haemorrhagic cystitis (55%), slow engraftment (59%), prolonged thrombocytopenia (68%), encephalitis (5%). Six (60%) patients with CMV infection after allogeneic and 1(8%) patient with CMV infections after autologous stem cell transplantation were dead. The cytotest after allogeneic transplantation of the bone marrow reduced the risk of CMV infection from 62 to 36%. CONCLUSION: CMV infection influences prognosis both in allogeneic and autologous transplantation of hemopoietic stem cells. Cytotest lowers the risk of CMV development after transplantation of allogeneic bone marrow.

Adolescent↗
PubMed1999

[Immunomodulator Cycloferon in the comprehensive treatment of patients with acute non-lymphoblastic leukemia].

The therapeutic benefit and action of the immunomodulator Cycloferon were evaluated in patients with acute non-lymphoblastic leukemia. When administered in conjunction with chemotherapy during first complete remission, it reduced both early-onset relapse frequency and degree of cytostatic-induced immune deficiency. The drug's action is mediated by changes taking place in cytokine and interferon synthesis.

Acridines↗
PubMed1996

[Levels of complement components in plasma of onco-hematologic patients with defective hemopoiesis].

Immunochemical assay using monoclonal antibodies was carried out to determine levels of a number of complement components (C3 and its derivatives-C4 and C5) and immunoglobulins (lg) in plasma of patients with onco-hematological diseases involving defective hemopoiesis: leukemia, myelodysplastic syndrome (clonal diseases) or aplastic anemia (delayed clonal disease). The most significant disorders were registered in the concentrations of component C3 and its derivatives. In acute leukemia, the nature and extent of C3 splitting was found to depend on disease while Ig level-on stage. Myelodisplasia usually involved a 2-3-fold decrease in C3 level matched by a rise in the concentrations of its derivatives-C3-like form and C3a fragment. Reduced C3 levels matched by increased ones of Ig were observed in some cases of aplastic anemia. It is suggested that disturbances in complement component level may cause changes in cascade reactions of the complement in onco-hematological patients and thus indirectly influence immune response regulation processes.

Complement C3↗
PubMed1996

[Immunologic monitoring and immune reconstitution in recipients of allogeneic bone marrow].

The dynamics of different peripheral blood lymphocyte subpopulations (CD3+, CD4+, CD8+, CD22+, DR+, CD25+ and CD16+) and levels of serum cytokines TNFa and IL1 beta were evaluated in 10 patients with allogeneic bone marrow transplantation (BMT). It was established that initially low levels of practically all the lymphoid subsets studied came back to normal in patients with favorable post-BMT course, while, in unfavorable post-BMT course (GVHD or relapse), the levels of said lymphoid subsets remained unchanged or even dropped. Post-BMT increase in serum TN alpha level can be of prognostic value for GVHD development whereas serum IL1 beta level does not correlate with post-BMT course.

Bone Marrow Transplantation↗
PubMed1996

[The optimization of the infusion therapy procedure in patients with acute leukemias].

In a trial of 202 patients with acute leukemia (AL) the authors studied the effect of volume and quality of infusion therapy (forced diuresis 2.5 l/m, parenteral nutrition, hemocomponent therapy) on early mortality, frequency of complications, complete remission, overall and relapse-free survival. It is shown that the response in remission induction depends on the scope and quality of infusion therapy. Balanced complete infusion therapy led to a complete remission in 75% and 92% of patients with acute nonlymphoblastic and acute lymphoblastic leukemia, respectively, compared to 29 and 50% for infusion-untreated patients. Early lethality was 6 and 0%, 42 and 18%, respectively. Higher efficacy of acute leukemia treatment in adjuvant balanced infusion therapy results from lower toxicity of chemotherapy and possible performance of induction therapy without reduction of drug doses.

Adolescent↗
PubMed1996

[Bone marrow transplantation in the treatment of acute leukemias].

The effect of bone marrow transplantation on 4-year leukemia recurrence-free survival of patients with acute myeloid and lymphoblastic leukemia has been studied in 11 and 16 patients, respectively. Autologous and allogeneic bone marrow transplantations during the first complete remission of acute leukemia have improved the survival compared to chemotherapy from 44 to 75% in acute myeloid leukemia and from 35 to 60% in acute lymphoblastic leukemia.

Adolescent↗
PubMed1995

[Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia].

The effectiveness of domestic alpha 2-interferon preparation reaferon was studied in vivo and in vitro for eradication of pathological hemopoietic clone in chronic myeloid leukemia. Reaferon administration for 1-30 months produced cytogenetic remission in 7%, hematological remission in 21%, partial hematological remission in 36% of the patients. Reaferon is indicated in chronic myeloid leukemia without splenomegaly. In the disease progression reaferon is uneffective. Mechanism of reaferon therapeutic action comprises three components: a direct antiproliferative effect on hemopoietic precursor cells, activation of cellular immunity, an effect on stem cell microenvironment.

Adult↗
PubMed1993

[The prognostic role of determining spontaneous leukocyte DNA damage and that occurring during chemotherapy in leukemia patients].

The authors studied spontaneous DNA damages and the extra plan synthesis of DNA in various leukemias (chronic lympholeukemia, chronic myeloleukemia, acute leukemia) to predict the natural course of leukemias and the efficiency of chemotherapy. The level of genuine DNA breaks, which had been determined by the nic-translation test, was lower in peripheral blood cell DNA in all leukemias than that in the lymphocytes and granulocytes from donors. On the contrary, the levels of alkaline-labile DNA sites and nuclear matrix protein-bound DNA in the mature and maturing leukemia cells are high and decrease with progression of chronic lympholeukemia and chronic myeloleukemia. The extra plan DNA synthesis largely reflects the cellular levels of genuine DNA breaks, and the ultraviolet-induced DNA repair capacity is the highest in the lymphocytes in chronic lympholeukemia and particularly in the blasts in acute leukemia. The efficiency of chemotherapy was predicted during chemotherapy from the intensity of formation of genuine blast cell DNA breaks.

Antineoplastic Agents↗
PubMed1993

[A comparative analysis of the effect of alpha 2-interferon (reaferon) therapy on the morphofunctional state of the bone marrow in patients with chronic myeloleukemia].

Marrow trepan biopsy was performed in 11 patients upon diagnosis of chronic myeloid leukemia and in clinicohematological remission of the disease. The patients were treated with alpha 2-interferon (reaferon) versus conventional myelosan (6 and 5 patients, respectively). The biopsies were studied histomorphometrically. In reaferon group the number of megakaryocytes and endosteal stromal cells diminished. This may be due to an indirect action of reaferon on hemopoietic tissue via endosteal cells of the marrow stroma. Reaferon is recommended for myeloid leukemia chronic with a granulocytic-megakaryocytic histological variant of the disease.

Adolescent↗
PubMed1990

[A method of determining erythrocyte deformability].

A simple method for determining red cell deformability is suggested, based on red cell packing during centrifugation. This method was used to study red cell deformability in patients with essential hypertension and angina of effort and found it reduced.

Adult↗
PubMed1989

[Hemostasis and T-cell immunity in lung cancer patients].

Complex examination of hemostatic system and T-cell-mediated immunity in 19 cases of stage II-IV lung cancer showed an increased activity of blood coagulation system to be associated with a decrease in OKT3+, OKT11+ and OKT4+ T-lymphocyte subsets levels. A reverse correlation was established between plasma--Willebrand's factor level and those of OKTè+ and OKT8+ lymphocytes whereas a direct one--between blood-platelet aggregate level and that of OKT4+. The data obtained emphasized the need to consider the status of hemostatic system when evaluating the function of cell-mediated immunity.

Adult↗
PubMed1989

[The rheologic aspects of washed donor erythrocytes].

Washing off donors' red blood cell pack with NaCl isotonic solution results in improvement of red blood cell rheologic properties: their aggregation reduces, deformability increases, osmotic resistance rises. Heparin addition to the washing off solution in a dose of 5 IU/ml prevents development of antiheparin activity in red blood cells after washing off. Application of washed-off red blood cells of donors has advantages as compared to transfusion of the whole blood.

Blood Donors↗
PubMed1988

[The role of the system of hemostasis in the development of vascular lesions in diabetes mellitus].

The examination of 179 patients with diabetes mellitus has shown that the mechanisms of vascular wall damage and changes in the system of hemostasis are different in type I and II diabetes mellitus. In type I diabetes mellitus vascular wall damages are associated with carbohydrate metabolic derangements, changes in the platelet link of hemostasis and blood coagulation system. In type II diabetes mellitus vascular wall damages are associated with lipid metabolic derangements and changes in the erythrocytic link of hemostasis.

Adult↗
PubMed1988

[The role of hemostasis and rheologic properties of blood in stable and progressive exertion-induced stenocardia].

Patients with angina of effort, both its stable and progressive variants, show hypercoagulative hemostatic shifts and a deterioration of blood rheologic properties, the changes being more pronounced in progressive angina. Vascular-wall changes, dependent on the level of plasma Willebrand's factor, are closely related to clinical severity of angina of effort. The latter is also related to changes in blood rheology (increased erythrocyte aggregation, reduced erythrocyte deformation and high platelet adhesion).

Adult↗